Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers
To evaluate azithromycin ocular conjunctiva concentrations 7 and 14 days after treatment initiation.
To assess ocular and systemic tolerance/safety and azithromycin tear concentrations on Day 7
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||Comparison of Azithromycin Level in Tears and in Conjunctiva After Repeated Instillations of T1225 1.5% Eye Drops or After a Single Per Os Administration of Zithromax® (Azithromycin 1g), in 36 Healthy Volunteers|
- Azithromycin Ocular Conjunctiva Concentrations on Days 7 and 14.
- Azithromycin Tear Concentrations on Day 7.
|Study Start Date:||February 2003|
|Estimated Study Completion Date:||March 2003|
The aim of the present study was to compare azithromycin tear and conjunctival ocular concentrations after one instillation of T1225 1.5% eye drops, twice a day during one day versus one instillation of T1225 1.5% eye drops, twice a day during 3 days versus an oral single dose of 1g azithromycin.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00356772
|Principal Investigator:||Claude DUBRAY, Professor||Centre de Pharmacologie Clinique - Clermont-Ferrand (France)|